About this trial
The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will collect urine and stool samples at home that will be sent to outside laboratories for testing.
Eligibility criteria
Qualifiers
A CF Carrier identified via genetic testing
No previous CF carrier test results
Disqualifiers
CF patient status
Unable to speak English
Currently pregnant
Unable to provide written informed consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Philip Polgreen
Lead sponsor
University of Iowa
Sponsor institution
National Institutes of Health (NIH)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator